Octave

4 articles with Octave

• Octave Bioscience Announces Strategic Investment from the Merck Global Health Innovation Fund to Transform Disease Measurement and Care for Patients with Neurodegenerative Diseases

  10/11/2021

  Octave Bioscience announced today that the Merck Global Health Innovation Fund (Merck GHIF) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.

• Octave Secures $20 Million in Series B Funding to Expand Mental Healthcare Access

  5/25/2021

  Octave, an innovator in outcomes-focused behavioral health, announced that it has raised $20 million in Series B funding, bringing its total raised to $34 million.

• Octave Bioscience to Present New Analyses Addressing the Complex Unmet Needs of Multiple Sclerosis Through Quantitative and Image-Based Measurement of Multiple Pathways and Their Biomarkers at the ACTRIMS Forum 2021

  2/26/2021

  Octave Bioscience (Octave), the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of five posters at the ACTRIMS Forum 2021.

• Octave Bioscience Secures $32 Million Series B Financing

  12/17/2020

  Northpond Ventures leads round New investors include Deerfield Management and Casdin Capital. All existing investors participated including The Blue Venture Fund, Echo Health Ventures and Section 32 Funds will be used to complete development of Octave Bioscience’s Comprehensive Care Platform and initiate early commercial activities